Samjin Pharmaceuticals Co., Ltd. (KRX:005500)

Market Cap	284.99B +33.1%
Revenue (ttm)	274.03B +45.0%
Net Income	21.89B +49.0%
EPS	1,727.82 +52.0%
Shares Out	12.26M
PE Ratio	13.46
Forward PE	13.97
Dividend	800.00 (4.47%)
Ex-Dividend Date	Dec 29, 2025

Volume	582,147
Average Volume	47,715
Open	19,880
Previous Close	17,900
Day's Range	19,250 - 23,250
52-Week Range	16,990 - 23,250
Beta	0.17
RSI	81.65
Earnings Date	Feb 3, 2026

About Samjin Pharmaceuticals

Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clin...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1968
• Employees: 586
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 005500

Financial Performance

In 2022, Samjin Pharmaceuticals's revenue was 274.03 billion, an increase of 9.58% compared to the previous year's 250.07 billion. Earnings were 21.89 billion, a decrease of -22.92%.